Intellia Therapeutics Inc

NTLA

$65.70

+427.32% (1 year change)

Avg closing price

Price range

Market Cap

$4.77 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$6.6 Million

Total revenue in the last quarter.

Net Income

-$42.2 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

-$2.40

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-35.55x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-42.4 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Intellia Therapeutics Inc

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.

News

FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews

FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews

Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News

FXNews24 FXNews24, 2 months ago
John M. Leonard Sells 109,889 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock

John M. Leonard Sells 109,889 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 109,889 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $64.00...

Watchlist News Watchlist News, 3 months ago
Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com

Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com

Raymond James Stick to Their Buy Rating for Intellia Therapeutics

Investing.com Investing.com, 3 months ago